Intravenously administered 2′-deoxycytidine suppresses mouse myeloma tumor growth

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 2, 2012, Pages 251-255

  Iwazaki, Ayano ^a   Imai, Kimie ^a   Nakanishi, Kunio ^a   Yoshioka, Masanori ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

2 deoxycytidine; Anti tumor; Survival

Indexed keywords

DEOXYCYTIDINE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG LIVER LEVEL; ENZYME IMMUNOASSAY; IN VIVO STUDY; INOCULATION; KIDNEY; MALE; MOUSE; MYELOMA; NONHUMAN; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; SINGLE DRUG DOSE; SPLEEN; SURVIVAL TIME; TREATMENT DURATION; TUMOR WEIGHT;

ANIMALS; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FLUOROURACIL; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; SPLEEN; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84856571278     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.251     Document Type: Article

References (12)

1. Silagi S. Metabolism of 1-β-D-arabinofuranosylcytosine in L cells. Cancer Res., 25, 1446-1453 (1965).
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48, 4024-4031 (1988).
3. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine). Cancer Res., 50, 4417-4422 (1990).
4. Momparler RL, Goodman J. In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res., 37, 1636-1639 (1977).
5. Iwazaki A, Imai K, Nakanishi K, Yoshioka M. Changes in 2′-deoxycytidine levels in various tissues of tumor-bearing mice. Oncol. Lett., 1, 999-1004 (2010).
6. Darwish I, Akizawa T, Hirose K, Omura K, EL-Rabbat N, Yoshioka M. Preparation of a specific monoclonal antibody against 2′-deoxycytidine. Anal. Chim. Acta, 365, 121-128 (1998).
7. Moyer JD, Malinowski N, Ayers O. Salvage of circulating pyrimidine nucleosides by tissues of the mouse. J. Biol. Chem., 260, 2812-2818 (1985).
8. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur. J. Nucl. Med. Mol. Imaging, 38, 711-721 (2011).
9. Osogoe B, Ueki A. A radioautographic study of the utilization of deoxycytidine for the formation of deoxyribonucleic acid-thymine in lymphocytes. J. Cell Biol., 46, 403-405 (1970).
10. Osogoe B, Tyler RW, Everett NB. The patterns of labeling of germinal-center cells with tritiated deoxycytidine. J. Cell Biol., 57, 215-220 (1973).
11. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem., 274, 18470-18476 (1999).
12. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell, 102, 553-563 (2000).